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Scintillation proximity assayMembrane proteins (MPs) are prevalent drug discovery targets involved in many cell processes. Despite their
high potential as drug targets, the study of MPs has been hindered by limitations in expression, puriﬁcation
and stabilization in order to acquire thermodynamic and kinetic parameters of small molecules binding. These
bottlenecks are grounded on the mandatory use of detergents to isolate and extract MPs from the cell plasma
membrane and the coexistence ofmultiple conformations, which reﬂects biochemical versatility and intrinsic in-
stability ofMPs. In thiswork ,we set out to deﬁne a new strategy to enable surface plasmon resonance (SPR)mea-
surements on a thermostabilized and truncated version of the human adenosine (A2A) G-protein-coupled
receptor (GPCR) inserted in a lipid bilayer nanodisc in a label- and detergent-freemanner by using a combination
of afﬁnity tags and GFP-based ﬂuorescence techniques. We were able to detect and characterize small molecules
binding kinetics on a GPCR fully embedded in a lipid environment. By providing a comparison between different
binding assays in membranes, nanodiscs and detergent micelles, we show that nanodiscs can be used for small
molecule binding studies by SPR to enhance the MP stability and to trigger a more native-like behaviour when
compared to kinetics on A2A receptors isolated in detergent. This work provides thus a new methodology in
drug discovery to characterize the binding kinetics of small molecule ligands for MPs targets in a lipid
environment.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Small molecule interactions with target proteins are of central
importance in drug discovery research and are at the heart of many cel-
lular processes such as synaptic transmission regulation, enzyme catal-
ysis, signal transduction and immune response. Membrane proteins are
key players inmost of these processes and represent an increasingnum-
ber of potential therapeutic targets of high interest. They also representplasmon resonance; GPCR, G-
CXCR4, C-X-C chemokine recep-
branescaffoldprotein;SPA,scin-
C, ﬂuorescence size exclusion
CHS, cholesteryl hemisuccinate;
lmitoyl,2-oleoyl-sn-glycero-3-
3-phosphoglycerol; Ysi, yttrium
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et).
. This is an open access article underthe largest family of proteins targeted bymarketed small molecules and
GPCRs constitute 25% of the all drug-target families of approved medi-
cines [1,2]. Therefore, deciphering and characterizing binding kinetics
of candidate drug molecules is a crucial and determinant step in the
development of new drugs acting on MPs in order to characterize
their mode of action on a speciﬁc pathway and their association with
and dissociation from target proteins. While the crystal structures of
themain classes of GPCRs have been elucidated in presence of agonists,
antagonists or inverse agonistswithin the last decade, greatly increasing
our understanding of the molecular mechanisms underlying ligand
binding and receptor activation [3–5], studies about the kinetics of
these compounds in the cell membrane context remain limited to
radioligand assays on membranes and mostly to molecules showing
slow dissociation proﬁle.
Surface plasmon resonance (SPR) biosensors represent a well
established method to study ligand–protein interactions and enables
the accurate assessment of kinetic parameters as association (kon) and
dissociation rates (koff), and also dissociation equilibrium constant
(KD), and inhibition constants (IC50 and Ki) [6]. SPR also possesses the
advantage of being a ‘label-free’ technology in a sense that thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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radioactive labelling. Nevertheless, the target protein still needs to be
immobilized on the SPR chip surface, a thin gold layer coated with a
carboxymethyl dextran matrix. Several methods exist to perform
immobilization of target molecules. The widely used amine coupling
covalently links the amine groups present on the protein to chemically
activated carboxyl groups of the dextran molecules. While very
efﬁcient, this coupling can be detrimental for the activity of the
immobilized protein due to acidic conditions used by the protein cou-
pling step. For this reason, SPR measurements often require alternative
coupling strategies or the presence of tags on the target protein for
immobilization purposes. Developing SPR assays with isolatedMPs rep-
resent a formidable challenge in several aspects. MPs are extracted from
the cell membrane with detergents used subsequently throughout the
entire puriﬁcation process and in the SPR running buffer. The detergent
micelle is a highly dynamic environment with constant exchanges
between the monomeric molecules of detergent and the micelle
which represents a non-native environment for the solubilized protein
differing signiﬁcantly from the membrane bilayer. Another difﬁculty of
working with MPs is the high versatility of their conformational states,
which are in fast equilibrium. Isolating ﬂexible MPs in detergent might
not provide a sufﬁciently stable environment in which the protein can
undergo the full spectrum of its natural conformational landscape or
which can lead to stabilization of an inactive state not suitable for bind-
ing experiments. For this reason, it is often required to stabilizeMPs in a
speciﬁc conformation by extensive campaigns of mutagenesis com-
binedwith thermostability assays. GPCRs are usually stabilized in a spe-
ciﬁc conformation towards a class of ligands increasing their intrinsic
stability and enabling biophysical measurements [7].
In addition, the immobilization of themembrane protein on the SPR
biosensor via a tagmight also impair the activity of the protein depend-
ing on its exact site of immobilization and orientation on the chip sur-
face, which can block the ‘extracellular’ or ‘intracellular’ side of the
protein. Despite all these bottlenecks, few studies have been successful
in demonstrating binding of small ligands on stabilized GPCRs solubi-
lized in detergent by SPR: the neurotensin receptor (NTS1) [8,9], the
turkey β1 adrenergic receptor [10,11], the human A2A adenosine recep-
tor [10,12,13] and the native human β2 adrenergic receptor [14] and
chemokine receptors CXCR4 and CCR5 solubilized in mixed detergent/
lipids micelles [15,16].
In order to circumvent the use of detergent, new solubilizing
agents have been developed such as amphipols, synthetic surfac-
tants and block copolymers [17]. Among these new technologies,
nanodiscs have emerged as an alternative option and powerful
tool, which has already been used for immobilization on an SPR
chip of monotopic MPs [18], membrane associated enzymes [19]
and the endothelin receptor [20], a class A GPCR but not yet for mon-
itoring of small molecule binding events by SPR. Nanodiscs are size-
tunable patches of lipids organized in a lipid bilayer whose hydro-
phobic edge is encircled by a dimer of Membrane Scaffold Protein
(MSP), a derivative from the human Apolipoprotein 1A [21].
Nanodiscs facilitate isolation and stabilization of MPs in a ‘mem-
brane-like’ environment. They also allow for measuring kinetic
parameters by SPR of small molecules on MPs fully embedded in a
lipid bilayer, bringing the acquired data closer to what might happen
in a native cell membrane. Finally, nanodiscs would enable a com-
plete ‘label-free’ technology because the target protein itself no lon-
ger needs to be tethered to the chip, rather the complex can be
immobilized through an engineered MSP. Here we report an SPR-
based kinetic study for small molecules binding to the human A2A
receptor incorporated in nanodiscs formed by a modiﬁed MSP pro-
tein carrying a C-terminal C9 tag and immobilized via the 1D4 anti-
body and via a His tag present on the C-terminus of the receptor.
We also compare the binding kinetics of detergent solubilized versus
nanodisc reconstituted receptor via two different techniques, SPR
and by SPA (scintillation proximity assay). To the best of ourknowledge, this is the ﬁrst report of small molecules binding events
monitored by SPR on a human GPCR incorporated in nanodiscs. Our
assay provides a novel drug discovery tool to assess the kinetic pa-
rameters of small molecules in a lipid environment that closely re-
sembles the lipid contents of cell membranes.
2. Methods
2.1. Protein expression and puriﬁcation
2.1.1. MSP1D1-C9 protein
The His-TEV-MSP1D1-C9 protein sequence was cloned into a
pet28a + plasmid between NcoI and BamHI. The plasmid containing
the His-TEV-MSP1D1-C9 coding sequence was transformed in
Escherichia coli BL21 (DE3) cells, and the production of the correspond-
ing protein was induced at OD = 0.8 with 0.5 mM IPTG at 20 °C over-
night. Cells were disrupted by sonication in the following buffer: Tris
50 mM at pH 7.5; NaCl 300 mM and protease inhibitors (Roche com-
plete EDTA-free, 1 tablet/50 ml); and supernatant was cleared by ultra-
centrifugation at 176 000 g at 4 °C. The latter was then incubated with
TALON cobalt resin (Clontech) at 4 °C for 1 h. The resin was washed
batchwise (10 CV) in Tris 50mMat pH7.5, NaCl 300mMand imidazole
10 mM, and the protein was eluted in Tris 50 mM at pH 7.5, NaCl
300mMand imidazole 400mM. Imidazole was removed either by dial-
ysis or by desalting columns and theHis tagwas cleaved by a 10% (w/w)
TEV protease digest at room temperature 1–2 h. TEV protease carries a
His tag and was then removed by afﬁnity and a short incubation with
TALON resin. TheﬁnalMSP1D1-C9 protein devoid of His tagwas collect-
ed in the ﬂow-through.
2.1.2. A2A receptor expression and puriﬁcation
The A2A-rant21 [22] receptor was cloned into a modiﬁed pFastBac1
vector and expressed in sf9 cells as a fusion with a GFP-10xHis tag at
its C-terminal extremity (after residue 316) separated from the A2A
sequence by a 3C protease cleavage site. Cells were infected at a density
of 2.106 cells/ml at a 0.5% (v/v) virus concentration. Cells were harvest-
ed after 72 h of expression by centrifugation in Tris 50 mM at pH 7.5;
NaCl 300 mM and protease inhibitors cocktail (ratio biomass/buffer of
1:8) and disrupted by Nitrogen cavitation (30 bar pressure) at 4 °C
under constant stirring (350 r.p.m). Cell debris were removed by low-
speed centrifugation (20 min at 570 g), and membranes were collected
andwashed by several cycles of gentle resuspensionwith a Ultra Turrax
and ultracentrigation (25 min at 92 500 g). Membranes were then sol-
ubilized in Tris 50 mM at pH 7.5, NaCl 300 mM, imidazole 20 mM, 1%
DDM (w/v), 0,1% CHS (w/v) and protease inhibitors (1 tablet per
50 ml of buffer) at a 1.75 ratio (Buffer volume (ml)/Biomass (g)) for
180min at 4 °C under stirring (300 rpm). Themixturewas then subject-
ed to an ultracentrifugation step at 4 °C, and the supernatant was incu-
bated with equilibrated TALON resin at 4 °C overnight under constant
stirring. The resin was then poured in a Pharmacia XK16 column and
washed in Tris 50 mM at pH 7.5, NaCl 300 mM, imidazole 40 mM,
0.05% DDM and 0.005% CHS, and the protein was ﬁnally eluted in Tris
50 mM at pH 7.5, NaCl 300 mM, imidazole 300 mM, 0.05% DDM and
0.005% CHS. The protein was then subjected to a size exclusion chroma-
tography (SEC) on a superdex 200 column run upon the following buff-
er: HEPES 50mM at pH 7.3, NaCl 300 mM, 0.05% DDM, 0.005% CHS and
TCEP 0.2 mM. The monomeric fractions were pooled, concentrated and
ﬂash frozen for storage and further use.
2.2. Nanodisc reconstitution and puriﬁcation
The lipids POPC and POPG (Avanti Polar Lipids) were dried under an
argon beam until creation of a ﬁlm which was then rehydrated for few
hours (typically 3 to 4 h) in 60mM sodium cholate at a ﬁnal concentra-
tion of 40 mM. POPC and POPG were then mixed in a 3:2 molar ratio,
and the solution was extruded by mechanical force with a mini-
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His:MSP1D1-C9:lipids) were mixed with an optimized molar ratio of
1:3:125, respectively, in HEPES 50 mM at pH 7.3; NaCl 150 mM; 0.05%
DDM and 0.005% CHS. The detergent was removed by incubating the
mixture with Biobeads (Biorad) for at least 2 h at 4 °C. The beads were
discarded, and a His afﬁnity chromatographywas performed on the su-
pernatant by incubation of TALON resin by 1 h incubation at 4 °C in
order to discard the nanodiscs which were not containing the
receptor. The nanodisc complex was then eluted in HEPES 50 mM at
pH 7.3, NaCl 300 mM and imidazole 400 mM, and the eluate was run
on a Superose 6 column under a HEPES 50 mM at pH 7.3, NaCl
300 mM running buffer. The fractions of the peak corresponding to
the nanodisc complex were ﬁnally pooled. To check the SEC fractions
and/or to screen for reconstitution conditions, FSEC runs were per-
formed on a Superdex 200 5/150 GL (GE healthcare) column with
HEPES 50 mM at pH 7.4; NaCl 300 mM as a running buffer.
To produce the empty nanodiscs sample, the same protocol was
used but the His tag was then kept on the His-MSP1D1-C9 protein.
2.3. Fluorescence analytical ultracentrifugation
Sedimentation velocity data were recorded at 20 °C (42,000 rpm,
with a 60Ti rotor, Spin Analytical SedVel60K centrepieces) using a
Beckman Coulter XLI analytical ultracentrifuge equipped with an Aviv
ﬂuorescence detection system (excitation at 488 nm, emission
at N 505 nm) [23]. The buffer was 50 mM Tris pH 7.5, NaCl 300 mM
for A2A-GFP-His in nanodiscs (used at 52 μg/ml with detector gain
2170/PGA 4) and supplemented with 0.05% DDM and 0.005% CHS for
A2A-GFP-His in mixed micelles (used at 100 μg/ml with detector gain
1801 V/PGA 4). Data were analysed with the programs Sedﬁt [24] and
Origin (OriginLab) and plotted with GUSSI (http://biophysics.swmed.
edu/MBR/software.html) and GraphPad Prism (GraphPad Software).
To compare the signal weighted sedimentation coefﬁcients of the two
samples, the values were corrected for buffer density and viscosity
and reported as sw20,w.
2.4. Scintillation proximity assay
For KD estimation, 15 μl of SPA beads, Ysi-poly-L-lysine-coated beads
for the sf9 membranes sample and Ysi copper beads for A2A-GFP-His
containing nanodiscs or A2A-GFP-His receptor solubilized in detergent
(Perkin-Elmer), 135 μl of the different samples (for membranes:
135 μg per well; for A2A-GFP-His receptor: 0.0052 μg per well and for
A2A-GFP-His containing nanodiscs: 0.0524 μg per well) and 50 μl of
radioligand ([3H]-SCH 58251) at the corresponding concentrations
were dispatched in an Optiplate-96 wells for a ﬁnal reaction volume
of 200 μl. The plate was then shaken for 30 min at 4 °C on a BioShake-
IQ prior measurement on a Top Count NXT device at 19 °C. The nonspe-
ciﬁc binding signal was estimated by adding large excess of cold ligand
in the well (typically 10 μΜ). As the cold compound was diluted in
DMSO, the corresponding concentration of DMSO (1%) was added in
the well corresponding to the total binding measurements. Each condi-
tion was measured in triplicates and triplicates were averaged to pro-
vide a mean value. The nonspeciﬁc binding value was then retrieved
from the total binding value, giving the speciﬁc binding CPM value. A
DPM value was furthermore derivatized from the speciﬁc binding
CPMvalue as explained in reference [25], and theﬁnal quantity of ligand
bound (inmmol) per μg of protein added to eachwell was then normal-
ized to the maximum value of each measurement and plotted against
the concentration of hot ligand. Due to the hydrophobic nature of the
hot ligand used in this study, the saturation of the signals was not
achieved at highest concentrations. This saturation value corresponding
to the maximal response has then been extrapolated on each data set
individually by a four-parameter nonlinear ﬁt, and only data sets meet-
ing good quality ﬁtting parameters (hill slope, standard deviations andconﬁdence intervals) in GraphPad Prism (GraphPad Software) were
kept and included in the global analysis.
For IC50 estimation, 15 μl of SPA beads, 135 μl of the different samples
(for A2A-GFP-His receptor: 0.0052 μg per well and for A2A-GFP-His con-
taining nanodiscs: 0.052 μg per well) and 50 μl of [3H]-SCH 58251 at a
constant concentration of 6 nM were ﬁrst mixed in an Optiplate-96
which was shaken for 15 min at 4 °C on a BioShake-IQ. The non-
radioactive competitor (ZM 241385 or XAC) was then added to the
well at the corresponding concentrations, and the plate was shaken
again 15 min prior measurement on Top Count NXT scintillation. The
data were treated the same way as for KD estimation. All ﬁnal curves
were ﬁtted in GraphPad Prism 6 with a stimulation (for KD) and inhibi-
tion (for IC50) nonlinear four parameters ﬁt.
2.5. SPR experiments
Direct binding studies were performed at 18 °C on Biacore 3000 or
T200 at ﬂow rate of 50 μl/min in the running buffer composed of Tris
20 mM at pH 7.8, NaCl 350 mM, and supplemented with 0.1% DDM
for experiments performed on the detergent solubilized receptor. At
the end of each compounds injections, the binding activity and stability
of proteins were tested with XAC ligand (at 200 nM). Association and
dissociation phases of tested ligands were monitored 120 and 300 s,
respectively. The ﬁnal binding experiment with small molecule ligands
was performed in the running buffer supplemented with 0.1% DMSO.
2.5.1. C9 immobilization of the A2A nanodiscs on CM5 or CM7 chip
The mouse Rho 1D4 antibody is ﬁrst immobilized on CM5 or
CM7 chips, previously activated in a 10 min injection of EDC (1-
ethyl-3-(3-dimethylaminopropyl)-carbodiimide) 0.2 M/NHS (N-
hydroxysuccinimide) 0.05 M mixture and contacted with antibody
at concentration of 10 μg/ml diluted in sodium acetate (pH 5.5) buff-
er until levels of immobilization reached between 15000 and 18000
RU. The chip was then deactivated with a 7 min injection of 1 M eth-
anolamine, pH 8.0. The A2A nanodiscs were then applied on the chip
and captured by the 1D4 antibody to reach typically levels between
4500 and 6500 RU. Empty nanodiscs were immobilized in the same
way for reference at levels between 3000 and 4500 RU, considering
mass differences of immobilized ligands (nanodiscs with A2A versus
empty nanodiscs).
2.5.2. His immobilization of puriﬁed A2A and nanodiscs on NTA chip
TheNTA chipswere preconditionedwith three 1-minpulses of EDTA
350 mM at pH 8.3. NiCl2 solution at 500 μM diluted in running buffer
was then injected for 3 min. To perform cross-linking of puriﬁed A2A
or nanodiscs with a dextran layer, ﬂow cells were ﬁrst activated 5 min
with an injection of 0.2 M EDC/0.05 M NHS solution at ﬂow rate of
10 μl/min. Proteins with His tags were then applied on the chip for cap-
turing (A2A nanodiscs: between 4500 and 6800 RU; empty nanodiscs:
between 3000 and 4500 RU; and puriﬁed A2A around 5000 RU).
Empty nanodiscs captured on the sensor surfacewas used as a reference
channel for nanodisc with A2A, whereas activated and deactivated NTA
sensor surface was used as a reference channel for puriﬁed A2A protein.
2.5.3. Data analysis
The raw sensorgrams corresponding to the receptor in nanodiscs are
triple referenced (signals from the reference channels without andwith
empty nanodiscs are subtracted from the acquired signal in the A2A
nanodiscs channels and corrected with a buffer injection) or double
referenced for the detergent solubilized receptor. All referenced
sensorgrams are analyzed with the BIAevaluation software 3000 (ver-
sion 4.1) and are ﬁtted with simultaneous kon/koff kinetic ﬁt and 1:1
interaction model including mass transfer.
Fig. 1.General strategy for nanodisc production and immobilization on an SPR chip. The receptor is produced as eGFP fusion protein for FSEC protein analytics and for easymonitoring the
proper receptor integration in the nanodiscs during their self-assembly. eGFP can be removed at any time thanks to the inserted 3C cleavage site. The different afﬁnity tags onMSP1D1 and
A2A-GFP-His allow with a simple afﬁnity chromatography step to remove the nanodiscs which do not contain the A2A-GFP-His receptors or to produce empty nanodiscs for controls and
reference purposes. PDB accession codes used to generate themodels: A2A, pdb: 3REY from the reference [27], the nanodiscmodel has been extracted from pdb 3JOO in reference [28] and
the eGFP from pdb 2YOG from reference [29].
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In order to set up and optimize the immobilizationmethods of GPCR
nanodiscs on an SPR chip and subsequent measurements of bindingevents, we chose to work with a thermostabilized human adenosine
A2A receptor carrying four point mutations (A54L, T88A, K122A and
V239A) and lacking 96 residues at the C-terminus (rant21 A2A) [22].
The rant21 A2A has been shown to be stabilized in the antagonist
1228 N. Bocquet et al. / Biochimica et Biophysica Acta 1848 (2015) 1224–1233bound formand can be relativelywell expressed in several heterologous
systems. Several A2A antagonist binding kinetics have been recorded by
SPR on the detergent solubilized protein [10,12]. Furthermore,
radiolabelled A2A antagonists exist to perform the SPA assays, providing
a robust system and a solid reference to optimize the experiments and
facilitate the comparison between the two different technologies, SPR
and SPA. We fused a GFP at the C-terminus, separated from the A2A
sequence by a 3C protease cleavage sequence and followed by a tag
comprising 10 histidine residues. This allows us, in a relatively quick
manner, to monitor the nanodisc formation by ﬂuorescence size exclu-
sion chromatography (FSEC) [26] and the homogeneity of the ﬁnal
nanodiscs by ﬂuorescence analytical ultracentrifugation while using
small amounts of sample. To form the nanodiscs, we expressed and
puriﬁed a variant of the MSP protein-called MSP1D1—carrying an
amino-terminal His tag for puriﬁcation purposes that can be removed
by TEV cleavage, and a C-terminal C9 tag (TETSQVAPA) to immobilize
the A2A/nanodisc complex via the 1D4 antibody on the SPR chip (Fig. 1).N
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aggregation of the A2A-GFP-His receptor upon overlipidation as
revealed by the increasing amount of ﬂuorescent material in the void
volume of the column (Fig. 2a) at ratios above 1:3:250. This condition
could be extrapolated to produce larger amounts of A2A-GFP-His
nanodiscs. To conﬁrm the homogeneity of the samples, we performed
ﬂuorescence analytical ultracentrifugation with A2A-GFP-His incorpo-
rated inMSP1D1-C9 nanodiscs and A2A-GFP-His in detergentmixedmi-
celles (DDM 0.05% + CHS 0.005%). A total of 82% of the total
ﬂuorescence signal (integrated main peak) can be attributed to A2A-
GFP-His in nanodiscs (sw20,w = 5.6 S), 95% in the case of the A2A-GFP-
His solubilized in detergent mixed micelles (sw20,w = 6.5 S). Thus,
both preparations can be consideredmonodisperse. Using a partial spe-
ciﬁc volume of vbar = 0.821 ml/g derived from the weight-fractions of
one A2A-GFP-His receptor, twoMSP1D1-C9molecules and an estimated
75 POPC/POPG lipid molecules in the nanodisc complex, a molecular
weight of 163 kDa can be calculated from the sedimentation velocity
data [9,30]. This corresponds well to the expected molecular weight of
168 kDa of this complex and shows that our nanodisc preparation con-
tains monomeric A2A-GFP-His receptor.Fig. 3. SPA binding assay with [3H]-SCH 58251. (a) KD estimation of different A2A-GFP-
His receptor preparations. The normalized speciﬁc binding CPM signals are expressed
in percentage of the maximal predicted saturation plateau value and plotted against
the concentration range of tritiated SCH 58251. The lines correspond to the mathe-
matical ﬁt of the experimental data (four variables nonlinear ﬁt). The error bars cor-
respond to the standard deviation calculated from 3 independent experiments. Blue
diamonds: A2A-GFP-His in native sf9 cell membranes. Grey squares: A2A-GFP-His sol-
ubilized in DDM detergent with CHS. Black squares: A2A-GFP-His solubilized in DDM
detergent without CHS. Red triangles: A2A-GFP-His reconstituted in nanodiscs. (b)
Competition assay with ZM 241385 and XAC with A2A-GFP-His solubilized in deter-
gent in panel b or reconstituted in nanodiscs in panel c.3.2. Binding parameters assessed by SPA
A scintillation proximity assay (SPA) is a fast way to determine
kinetic and binding parameters and is widely used in drug discovery
[25]. Normally, SPA is applied on puriﬁed MPs or full cells containing
the receptor. Nevertheless, the β2 adrenergic receptor [31] and the
bacterial leucine transporter [32] reconstituted in nanodiscs or
reconstituted high-density lipoprotein (rHDL) have already been sub-
jected to SPA, demonstrating the feasibility of the technique to deter-
mine KD, association and dissociation rate constants of radioligands on
MPs inserted in an artiﬁcial lipid bilayer. SPA with the tritiated [3H]
SCH 58251 A2A antagonist was used to experimentally determine its
dissociation equilibrium constant in four different assay formats: mem-
branes of sf9 cells expressing the A2A-GFP-His construct, the A2A-GFP-
His receptor puriﬁed in detergent supplemented or not with 0.005%
CHS and the A2A-GFP-His receptor reconstituted in nanodiscs (Fig. 3a).
SPA has the great advantage to enable measurements on membranes
of sf9 cells by using poly-L-lysine-coated Ysi beads. KD of [3H]SCH
58251 on A2A-GFP-His inside the cell membrane was determined with
a value of 0.93 ± 0.57 nM. The KD measured on isolated A2A receptor
in DDM and CHS and on A2A-GFP-His receptor reconstituted in
nanodiscs immobilized via the A2A His tag to Ysi copper beads were in
the similar nanomolar range: KD DDM = 7.98 ± 3.94 nM, KD DDM-
CHS = 6.15 ± 6.09 nM and KD nanodiscs = 14.86 ± 5.68 nM. Due to the
unspeciﬁc binding of [3H]SCH 58251 ligand at increased concentrations
of hot ligand, it was not possible to acquire reliable saturation values.
These have therefore been extrapolated by a nonlinear four-variable pa-
rameters ﬁt strategy. As the calculated KD value for A2A-GFP-His solubi-
lized in detergent is within the conﬁdence intervals of the KD obtained
for the A2A-GFP-His receptor in nanodiscs, we observe no signiﬁcant
difference in afﬁnity of SCH 58251 for A2A-GFP-His receptor once ex-
tracted from the membrane, but the afﬁnity is approximately 10
times better when A2A-GFP-His is still embedded in the native mem-
brane. Finally, competition assays (Fig. 3b and c) allowed us to deter-
mine IC50 of ZM 241385 and XAC (Xanthine Amine Congener) on
A2A-GFP-His in DDM + CHS (IC50 ZM 241385 = 12.17 nM; IC50 XAC =
236.4 nM) and in nanodiscs (IC50 ZM 241385 = 52.44 nM; IC50 XAC =
819.4 nM), two antagonists which have been cocrystallized with
A2A receptor [27]. The values determined with the SPA assay on the
rant-21 A2A mutant in this study (Table 1) are overall in good agree-
ment with the previously published values obtained with other
radiobinding methods [22] and on the wild-type protein [33,34]. To
decipher the kinetic parameters in deeper details, we analysed the
different samples in an SPR analysis.3.3. Real-time monitoring of small molecules binding by SPR
We ﬁrst assessed the antagonist binding activity of A2A-GFP-His iso-
lated in DDMmicelles by immobilization onNTA chip as represented on
Fig. 4a. We determined the binding constants by SPR of three antago-
nists (ZM 241385, SCH 58251 and XAC) in a running buffer containing
0.1% DDM (Fig. 4b, c and d). The protein binding activity level calculated
from the sensorgrams obtained with the detergent solubilized receptor
is 52% (with an estimated molecular mass of 80 kDa). The binding pa-
rameters derived from these measurements are listed in Table 2 and
Table 1
Binding parameters of A2A antagonists determined by SPA at 19 °C.
Compound MW (Da) logP SPA
Reference in membranes Detergent (DDM 0.05% + CHS 0.005%) Nanodiscs
KD (nM) koff (s-1) KD (nM) IC50 (nM) koff (s-1) KD (nM) IC50 (nM) koff (s-1)
XAC 428 1.62 ND ND ND 236.4 ND ND 819.4 ND
ZM 241385 337 2.52 ND ND ND 12.17 ND ND 52.44 ND
SCH 58251 345 3.02 0,93 ± 0.57 1.57E-02 7,98 ± 3.94 ND 0.85E-02 14,86 ± 5.68 ND 0.84E-02
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A2A construct [10]. A2A-GFP-His nanodiscs were then immobilized via
the His tag present on the carboxy terminal tail of the GFP fused to the
receptor by direct afﬁnity coupling on nickel NTA chip, reaching levels
of immobilization typically around 6000 RU (Fig. 4a). This is a reason-
able amount for small molecules binding events detection on large
objects as nanodiscs as the amplitude of the recorded signal is propor-
tional to the ratio between the molecular size of the binder (in this
study, ranging from 337 to 428 Da) and the size of the target (estimated
around 163 kDa for the A2A-GFP-His nanodiscs). Furthermore, this cap-
turingmethod allows immobilization of empty nanodiscs on a reference
channel and to cross-link the pre-captured nanodisc complex to the
chip by amine coupling (Fig. 4e, f, g and h). Cross-linking of nanodiscsFig. 4.Kinetic analysis at 18 °Cof A2A antagonists by SPR. (a, b, c andd)Dose–response curvesob
(5-10-15-20-40-60 and 80 nM), ZM 241385 (2-4-8-16-25-50-75 and 100 nM) and SCH 5825
performed on A2A containing nanodiscs immobilized through the C9 epitope present on the M
A2A containing nanodiscs immobilized through the His tag located on the receptor as shown inon the biosensor produces more stable baseline and avoid dissociation
of protein from sensor surface as previously reported on detergent sol-
ubilized A2A receptor [10]. Thus, it is possible to monitor signiﬁcantly
higher binding responses when compared to experiments with non-
cross-linked nanodiscs. In this conﬁguration, the application of antago-
nists solutions elicited responses between 5 and 10 RU of amplitude
allowing accurate characterization of binding kinetics of the 3 antago-
nists. Repetitive injections of concentration series of each compound
generate reproducible and saturable signals demonstrating the robust-
ness of the assay setup. In addition, the nanodisc environment greatly
increases the stability of the A2A receptor as it could be stored for
months at 4 °C, and data were recorded for several weeks with the
same chip without signiﬁcant loss of activity (approximately 80% activetainedwith thedetergent solubilizedHis tag captured receptor as shownonpanel a for XAC
1 (5-10-20-30-40-60 and 100 nM) respectively. (e, f, g and h) The same kinetic analysis
SP1D1 protein as shown in the inset panel e. (i, j, k and l) Kinetic analysis performed on
panel i.
Table 2
Binding parameters of A2A antagonists determined by SPR at 18 °C.
Compound MW
(Da)
SPR
Detergent (DDM 0.1%) Nanodiscs
kon (M-1 s-1) koff (s-1) KD (nM) C9 immobilization His immobilization
kon (M-1 s-1) koff (s-1) KD (nM) kon (M-1 s-1) koff (s-1) KD (nM)
XAC 428 7.36E+05 ±
3.28E+05
1.82E−02 ±
5.23E−03
24.70 ± 11.11 1.57E+06 ±
1.02E+06
1.57E−02 ±
1.64E−02
9.90 ± 2.13 2.09E+06 ±
2.20E+06
1.46E−02 ±
1.43E−02
6.98 ± 1.07
ZM241385 337 3.30E+06 ±
1.43E+06
5.99E−03 ±
1.18E−03
1.82 ± 0.49 2.48E+07 ±
8.92E+06
3.55E−03 ±
6.66E−04
0.14 ± 0.16 1.10E+07 ±
1.50E+07
3.11E−03 ±
2.84E−03
0.28 ± 0.0051
SCH 58251 345 7.34E+05 ±
1.05E+06
1.60E−02 ±
7.21E−03
21.7 ± 7 3.67E+06 ±
1.36E+06
7.62E−03 ±
2.74E−03
1.98 ± 0.46 1.42E+06 ±
2.57E+05
3.82E−03 ±
1.92E−04
2.70 ± 0.70
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cross-linking on protein binding activity and on binding constants. We
next immobilized the nanodisc complex via the MSP1D1 protein. After
the covalent immobilization of the 1D4 antibody on CM5 or CM7 chip
by classical amine coupling, the A2A nanodiscs were captured via the
C9 epitope by the antibody (Figs. 1 and 4i). A similar high level of immo-
bilization (6000–7000 RU) was reached, and the biosensor was equili-
brated with the running buffer until achieving of stable baseline. We
could also attach C9 containing empty nanodiscs on a reference channel
and substract the reference sensorgram from theA2A-GFP-His nanodiscs
sensorgram. Fig. 4 summarizes the dose–response sensorgrams obtain-
ed for the three compounds on detergent solubilized A2A-GFP-His re-
ceptor (Fig. 4b,c and d), A2A-GFP-His nanodiscs immobilized via the
receptor (Fig. 4e,f g and h) and via the MSP1D1 protein (Fig. 4i, j, k
and l) and the binding constants are reported on Table 2.While binding
constants are very similar for XAC (KD A2A-GFP-his/XAC= 24.7± 11.11 nM
and KD nanodiscs/XAC = 9.97 ± 2.13 nM with highly similar association
and dissociation rates), for ZM 241385 (KD A2A-GFP-His/ZM = 1.82 ±
0.49 nM and KD nanodiscs/ZM = 0.14 ± 0.16 nM) and SCH 58251 (KD
A2A-GFP-His/SCH = 21.7 ± 7 nM and KD nanodiscs/SCH = 1.98 ± 0.46 nM),
the KD values are one order of magnitude shifted to lower values for
the receptor reconstituted in nanodiscs. This difference could not be
detected by the SPA assay where KD for SCH 58251 are all in the
nanomolar range. These discrepancies in KD can be almost completely
explained by differences in kon rates, which are faster (around 10 fold)
for the receptor incorporated in nanodiscs compared to the detergent
solubilized receptor (Table 2). We tried to test if these differences
stem from the presence of CHS in the A2A-GFP-His nanodiscs, which is
absent in the running buffer of the SPR experiments on the detergent
solubilized protein, but were unable to perform convincing measure-
ments once the running buffer containing 0.1%DDMwas supplemented
with 0.001% CHS, pointing out the fact that ZM 241385 and even more
SCH 58251 do not behave well in presence of CHS. It is important to
note that no binding signal has been detected on empty nanodiscs (ref-
erence channel), indicating that there is no detectable pre-binding of
the antagonists to the nanodiscs. The results obtained on the detergent
solubilized receptor are in good agreementwith the previously reported
binding constants [10].
4. Discussion
To address the question whether detergent puriﬁed GPCRs have
similar kinetic behaviour than membrane embedded GPCRs, we devel-
oped nanodisc-based SPR assay to determine small molecules binding
parameters on A2A receptor inserted in a membrane-like environment.
In this study, we established and compared various nanodiscs immobi-
lization strategies, either via the receptor through the C-terminally
located His tag or via the nanodisc itself through a C9 epitope located
on the MSP protein. We determined kinetic constants of small mole-
cules on the A2A receptor embedded in those lipid bilayer nanodiscs
by SPR, and compared them to the kinetics measured on detergentsolubilized receptors. We also performed and determined binding
parameters by SPA, a radiobinding assay, that we compared to values
obtained with SPR. We detected some deviations and differences
between the receptor isolated in detergent or reconstituted in
nanodiscs which might have important signiﬁcance for drug discovery.
4.1. Observed kinetic parameters are independent on the immobilization
procedure
Overall, we assessed the inﬂuence of GPCR immobilization on antag-
onist binding kinetics. Nanodiscs were designed to allow immobiliza-
tion of A2A nanodiscs on the chip via the nanodiscs or via a tag on A2A
in order to check whether attaching the receptor directly on the chip
(with or without cross-linking) via its own tag could affect the binding
kinetics. Table 2 shows that neither on- nor off-rates or KD were signif-
icantly affected by the different immobilization procedures (Fig. 4).
Moreover, the presence of the GFP-His tag on the receptor does not
have detectable inﬂuence on binding constants (Supplementary
Fig. 2), highlighting the fact that the main inﬂuencing parameter on ki-
netic rates is the membrane environment. In agreement with this idea,
we observed lower KD values for SCH 58251 by SPA on membranes of
cells expressing A2A-GFP-His and for ZM 241385 and SCH 58251 on
theA2A-GFP-His nanodisc samples by SPR. Even ifwe cannot completely
rule out the possibility of an inﬂuence of the way of anchoring the sam-
ple on the SPA beads via the negatively charged lipids present in the cell
membrane, the native membrane provides obviously the best environ-
ment for the binding activity of the A2A receptor. Nevertheless, the SPA
experiment requires labelled compounds, and membrane samples can-
not behandledwith the SPR technology. Hence, thenanodisc represents
a minimal lipidic environment enabling label-free SPR measurements
with both ‘extracellular’ and ‘intracellular’ sides accessible for ligand
binding.
4.2. Nanodiscs further stabilize the inserted A2A receptor
A very important parameter for SPR experiments is the stability of a
protein as deﬁned as the time it remains active. Stability is one of the
main limiting factors when working with isolated MP whose ligands
have slow kinetics parameters or when performing SPR screening activ-
ities. We showed in this study that the A2A receptor incorporated in
nanodiscs possesses increased binding activity (80% when inserted in
nanodiscs versus 52% in detergent micelles) and stability allowing SPR
data acquisition on the same chip without regeneration for two to
three weeks at least while the activity of the detergent solubilized A2A
is almost completely lost after 80 h. The nanodisc sample could also
be stored at 4 °C for 6 months prior immobilization on the chip without
signiﬁcant loss of activity (Supplementary Fig. 2). This represents a clear
advantage of the nanodisc technology over detergent-GPCR-micelles as
it could enable larger SPR screens on GPCR reconstituted in lipid bilayer.
While any MP can in principle be inserted into nanodiscs highlighting
the universality of the method, a stabilized version of the MP might
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tion on the biosensor chip in order to generate a detectable signal. This
is a limitation of the method in case wild-type GPCRs are absolutely
required for kinetic studies as theymight be too unstable. To determine
whether this methodology is applicable to native MPs would require
further investigations.
4.3. Inﬂuence of the nanodisc environment on kinetics parameters
One of the striking features observed in this study is that associa-
tion rates for two compounds (ZM 241385 and SCH 58251) appear
signiﬁcantly faster (one order of magnitude) when the A2A receptor
is inserted in nanodiscs resulting in stronger afﬁnities than those
measured on detergent solubilized receptors. One hypothesis to
this observation could be that the presence of a lipid bilayer modiﬁes
the access pathway of the ligand to the receptor. It has been shown
on the β1 adrenergic receptor that drug-membrane protein associa-
tion rates are governed by the ‘membrane afﬁnity’ of the compound
[35] that leads to a partial partitioning inside the lipid bilayer. The
non-homogenous distribution of a compound with a higher local
concentration in the membrane close to the receptor gives rise to a
higher receptor bound fraction and consequently to apparently in-
creased association rates. Interestingly, the most drastic deviations
are observed with ZM 241385. For this compound, indeed, the ob-
served association rate on A2A nanodiscs is 10 times faster than for
the detergent solubilized receptor. This observation is also true for
SCH 58251 but to a lower extent. This behaviour correlates with
the lipophilicity of the compounds as reﬂected by the logP values.
SCH 58251 (logP = 3.02) and ZM 241385 (logP = 2.52) have most
likely a good propensity to partition inside the lipid bilayer formed
by the nanodisc assembly. XAC whose binding constant on detergent
or nanodiscs solubilized receptors are very similar has a lower logP
value (1.62) and potentially partition less within the lipid bilayer.
In order to test whether the observed KD discrepancies could be
only explained by differences in kon rates, we estimated the koff
rates of [3H]SCH 58251 on A2A receptors still embedded in native
membranes and compared it to detergent and nanodiscs solubilized
receptors by time resolved SPA (Table 2 and Supplementary Fig. 3).
The obtained koff values are very similar to those measured with
SPR (koff/nanodiscs/SPR = 0.76 × 10−2 s−1 and koff/detergent/SPR
=1.60 × 10−2 s−1). Moreover, nanodiscs and detergent solubilized
A2A receptors do not show signiﬁcant koff rates differences (koff/mem-
branes/SPA = 1.57 × 10−2 s−1; koff/nanodiscs/SPA = 0.84 × 10−2 s−1 and
koff/detergent/SPA =0.85 × 10−2 s−1). These data conﬁrm that the main
factor affecting the ﬁnal KD is the association rate and not the disso-
ciation rate, at least for SCH 58251 antagonist. Although this is not a
deﬁnitive proof and we can rule out an additional effect of the intro-
duced mutations on the kinetic behaviour of the receptor in a lipid
environment, these observations point out the fact that the
physico-chemical properties of ligands and their ability to partition
inside lipid bilayer are crucial parameters having an important im-
pact on the local ‘micro kinetic’ of membrane proteins. An additional
piece of explanation could be the presence of CHS in the lipid compo-
sition of the nanodiscs. It has been shown that cholesterol binds to
A2A in the surrounding of helix VI and might act as an allosteric mod-
ulator [36]. It indeed displaces the side chain of the N253 towards the
ligand present in the binding pocket (in this case ZM 241385) creat-
ing additional hydrogen bonding and therefore potentially increas-
ing the afﬁnity of ZM 241385 for the A2A receptor. For all these
aspects, nanodiscs represent a wonderful tool, which was missing
in the SPR ﬁeld, to decipher these effects and this study shows that
they are good mimics of the cell membrane, at least for kinetic stud-
ies, in recapitulating some of the properties of themembrane. Never-
theless, more systematic investigations are clearly required to better
describe the inﬂuence of lipophilicity of ligands as well as the effects
of lipids on the kinetic.4.4. Potential impacts of nanodisc-based SPR on drug discovery
The ﬁrst important impact is on the determination of ‘real or
improved’ kinetic parameters. To get closer to what really happens
inside a cell membrane when a ligand binds to a membrane protein
can greatly help in bridging different levels of experimentationwith-
in the drug discovery pipeline. An enhanced accuracy in kinetic con-
stants for a given compound and taking into account the effect of the
lipid environment on the binding properties might, if not fully
explain, at least highlight some discrepancies between in vitro assays
on a detergent solubilized membrane protein and the results of cell
assays in which plasma membrane has a great inﬂuence on the
binding activity of the same membrane protein. These advantages
can be extrapolated to screening activities like fragment based
screen by SPR on human integral membrane proteins incorporated
in nanodiscs. The presence of a lipid bilayer and its inﬂuence on the
membrane protein functionality might end up with different or
more biologically relevant hits. The output of such a screen could
be directly compared with what has already been done on detergent
solubilized GPCRs [11].
5. Conclusion
In this study, we demonstrated that SPR experiments can be per-
formed in a universal (applicable to all membrane proteins) and com-
plete ‘label-free’ manner that raises the possibility to study the
inﬂuence of agonistic or antagonistic ligands on the binding of G pro-
teins or β-arrestin as extracellular and intracellular sides of the GPCR
are accessible in this current setup. Kinetic studies on inﬂuence of signal
transducers binding on ligands afﬁnities, potencies, efﬁcacies or on ef-
fects of allosteric modulators as lipids can therefore be envisioned. The
reverse setup could also be tested by screening which G protein and
therefore which pathway is activated upon binding of a given ligand.
Finally, the nanodiscs allow the use of detergent-free conditions, in-
crease tremendously the stability of the protein inserted in and, there-
fore, represent a very good substitute to native membrane.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamem.2015.02.014.
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